6505--INTENT TO SOLE SOURCE Radiopharm - Lutathera & Pluvicto - Lebanon VAMC

INTENT TO SOLE SOURCE The Department of Veterans Affairs, Network Contracting Office 4 (NCO4) intends to sole source a contract for Lutathera & Pluvicto for the Lebanon VA Medical Center. All work is to be completed in accordance with statement of work. This sole source contract will be solicited and negotiated with Novartis Pharmaceuticals Corporation, 59 Route 10, East Hanover, NJ 07936-1080 under the deviation outlined in the Revolutionary FAR Overhaul (RFO) for FAR 8.4 - Ordering under the Federal Supply Schedule and GSAM/R 538.71, as required by Executive Order (E.O.) 14275, Restoring Common Sense to Federal Procurement, signed April 15, 2025. Deviation effective date: November 3, 2025. See attached Draft Statement of Work (SOW). The North American Industry Classification System (NAICS) code for this procurement is 325412. The Small Business Administration (SBA) size standard is 1300 employees. Interested vendors that can meet this requirement, shall identify their interest and capability, and respond to this notice by 11/03/2026 by 1400 pm EST. Interested vendors must send a capability statement, no more than one page in length; to include Company Name, SAM UEI Number, Socioeconomic Category, brief description of your business entities capability to handle this project at the Lebanon VA Medical Center. This Special Notice of Intent to Sole Source is for planning purposes only. No solicitation will be made available. This is not a request for quotations. All information shall be provided at no cost or obligation to the Government. Responses must be sent via email to the Contracting Specialist at cynthia.laemmerhirt@va.gov. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon the responses to this notice is solely at the discretion of the Government. If no responses are received, Contracting will proceed with the sole source negotiation with Norvartis Pharmaceuticals Corporation.